Dean F Bajorin

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903)
    Dean F Bajorin
    The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 7:E66-70. 2009
  2. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
  3. doi request reprint Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:4062-7. 2009
  4. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
  5. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
  6. pmc Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013
  7. doi request reprint Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:981-6. 2012
  8. doi request reprint The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor
    Atreya Dash
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:800-5. 2008
  9. doi request reprint Phase II study of everolimus in metastatic urothelial cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 112:462-70. 2013
  10. ncbi request reprint Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome
    James M McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:732-6. 2003

Research Grants

  1. CLINICAL RESEARCH METHODOLOGY CURRICULUM
    Dean Bajorin; Fiscal Year: 2004
  2. CANCER CHEMOTHERAPY TRAINING PROGRAM
    Dean Bajorin; Fiscal Year: 2007

Detail Information

Publications50

  1. doi request reprint Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903)
    Dean F Bajorin
    The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 7:E66-70. 2009
    ..There are also preclinical data to suggest that this drug might be active in nonhematopoietic malignancies, and transitional cell carcinoma cell lines are particularly sensitive to this agent...
  2. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  3. doi request reprint Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:4062-7. 2009
    ..This study sought to evaluate the efficacy and to additionally define toxicity...
  4. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
    ..69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02)...
  5. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  6. pmc Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013
    ..This trial evaluated the efficacy and safety of bevacizumab with GCa in advanced UC...
  7. doi request reprint Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:981-6. 2012
    ..The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents...
  8. doi request reprint The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor
    Atreya Dash
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:800-5. 2008
    ..The objectives of the current study were to determine the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with cIS NSGCT...
  9. doi request reprint Phase II study of everolimus in metastatic urothelial cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 112:462-70. 2013
    ..To maximize benefit from targeted agents such as everolimus, the preselection of patients based on molecular phenotype is required...
  10. ncbi request reprint Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome
    James M McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:732-6. 2003
    ....
  11. pmc Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
    Gopa Iyer
    Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA
    J Clin Oncol 31:3133-40. 2013
    ..We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery...
  12. doi request reprint Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY 10029, USA
    Clin Genitourin Cancer 9:27-30. 2011
    ..We retrospectively evaluated the activity of satraplatin in patients with cisplatin or carboplatin-refractory urothelial carcinoma and demonstrated lack of significant antitumor activity in this population...
  13. ncbi request reprint Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:5597-602. 2007
    ..3). CONCLUSION Patient selection factors have significantly improved the outcome of patients with CS IIA and IIB NSGCT without substantially increasing the proportion of patients exposed to chemotherapy...
  14. doi request reprint Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 102:1339-44. 2008
    ..Ongoing research will focus on individualized patient care, with biomarkers to predict a pathological complete response and the development of novel targeted therapies...
  15. ncbi request reprint Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 174:557-60; discussion 560. 2005
    ....
  16. doi request reprint Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urology 79:156-9. 2012
    ..We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival...
  17. pmc Genome sequencing identifies a basis for everolimus sensitivity
    Gopa Iyer
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 338:221. 2012
    ....
  18. ncbi request reprint Chemotherapy for good-risk germ-cell tumors
    Charles J Ryan
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Urol Oncol 20:244-50. 2002
    ..Bleomycin remains controversial in good-risk germ-cell tumors, but the literature suggests that both E(500)P for four cycles or BE(500)P for three cycles may be considered standard...
  19. ncbi request reprint Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer...
  20. ncbi request reprint Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  21. ncbi request reprint Salvage chemotherapy for patients with advanced pure seminoma
    Jacqueline Vuky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:297-301. 2002
    ..We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment...
  22. ncbi request reprint Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2781-8. 2005
    ..Since 1999, our criteria have excluded patients with persistent postorchiectomy elevation of serum tumor markers (STM) or clinical stage (CS) IIB disease from RPLND...
  23. pmc TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:1706-13. 2010
    ..We now report the efficacy of TI-CE with prognostic factors for disease-free survival (DFS) and overall survival (OS) in our full data set of 107 patients...
  24. doi request reprint Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5193-201. 2009
    ..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
  25. pmc Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
    Hikmat A Al-Ahmadie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
    J Pathol 224:270-9. 2011
    ..Histological review could thus aid in the development of targeted inhibitors of FGFR-3 by facilitating the identification of the subset of patients most likely to harbour activating mutations in the FGFR3 gene...
  26. doi request reprint Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine, Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 29:2432-8. 2011
    ..However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients...
  27. doi request reprint Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting
    David J Gallagher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:1284-93. 2008
    ..The authors reviewed the activity of several single agents and combination regimens in patients with UC. Emerging strategies for the measurement of response in clinical trials were also outlined...
  28. doi request reprint Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
    Satish K Tickoo
    Department of Pathology Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Center, New York, NY, USA
    BJU Int 107:844-9. 2011
    ....
  29. ncbi request reprint Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
    ..We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy...
  30. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  31. ncbi request reprint Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  32. ncbi request reprint Chemotherapy for teratoma with malignant transformation
    Alessia C Donadio
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:4285-91. 2003
    ..We report that chemotherapy has a role in selected patients with MT, determined by cell type...
  33. ncbi request reprint Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy
    Ellen A Ronnen
    Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6999-7004. 2005
    ..To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy...
  34. pmc Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer
    Andrea B Apolo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:3973-8. 2010
    ..This study investigated the value of FDG-PET/CT imaging in the management of patients with advanced bladder cancer...
  35. doi request reprint False elevation of human chorionic gonadotropin in a patient with testicular cancer
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Urol 7:230-3. 2010
    ..He was treated with four cycles of etoposide and cisplatin chemotherapy, but his hCG level had not returned to normal at the end of the treatment. Postchemotherapy CT showed no evidence of metastatic disease...
  36. pmc Novel strategies for treating relapsed/refractory urothelial carcinoma
    Gopa Iyer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Anticancer Ther 10:1917-32. 2010
    ..This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development...
  37. ncbi request reprint Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features
    Satish K Tickoo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Surg Pathol 10:23-32. 2002
    ....
  38. doi request reprint Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients
    Bruce Ng
    Department of Dermatology, New York University School of Medicine, 522 First Avenue, New York, NY 10016, USA
    Clin Cancer Res 14:6253-8. 2008
    ..In this study, we investigated the clinical relevance of HUI77 shedding in melanoma patient sera...
  39. pmc Clinical states model for biomarkers in bladder cancer
    Andrea B Apolo
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Future Oncol 5:977-92. 2009
    ..In this review, a clinical states model of bladder cancer is introduced and integrated into a paradigm for biomarker development. Biomarkers are systematically incorporated with predefined end points to aid in clinical management...
  40. pmc Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy
    Arjun Balar
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ther Adv Urol 3:107-17. 2011
    ....
  41. doi request reprint Phase II study of sunitinib in patients with metastatic urothelial cancer
    David J Gallagher
    Genitourinary OncologyService, Division of Solid Tumor Oncology, and the Departments of Radiology, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:1373-9. 2010
    ..No standard therapy exists for metastatic urothelial cancer (UC) that has progressed after initial chemotherapy. This trial was designed to assess the efficacy and tolerability of sunitinib in patients with advanced, previously treated UC...
  42. ncbi request reprint Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  43. ncbi request reprint Advances in urologic oncology: results progress from successful interdisciplinary research
    Dean F Bajorin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5479-81. 2006
  44. pmc The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Urology, New York University School of Medicine, New York, USA
    J Transl Med 5:49. 2007
    ....
  45. ncbi request reprint Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients
    Iman Osman
    Kaplan Comprehensive Cancer Center, New York, NY, USA
    Int J Cancer 111:934-9. 2004
    ..Further efforts are under way to confirm the potential predictive value of these markers in a prospectively designed study of a larger cohort of patients...
  46. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
    ..001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC...
  47. ncbi request reprint The graying of testis cancer patients: what have we learned?
    Dean F Bajorin
    J Clin Oncol 25:4341-3. 2007
  48. ncbi request reprint Novel blood biomarkers of human urinary bladder cancer
    Iman Osman
    New York University School of Medicine, New York 10016, USA
    Clin Cancer Res 12:3374-80. 2006
    ..We tested the hypothesis that blood cell gene expression can differentiate between bladder cancer and other genitourinary cancers as well as between bladder cancer and healthy controls...
  49. ncbi request reprint Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:5442-7. 2006
    ..These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium...
  50. ncbi request reprint The evolution of bladder cancer treatment: improvements in clinical management, enhanced clinical outcomes, and targeting newly identified molecular alterations
    Dean F Bajorin
    Semin Oncol 34:73-4. 2007

Research Grants4

  1. CLINICAL RESEARCH METHODOLOGY CURRICULUM
    Dean Bajorin; Fiscal Year: 2004
    ..abstract_text> ..
  2. CANCER CHEMOTHERAPY TRAINING PROGRAM
    Dean Bajorin; Fiscal Year: 2007
    ..This competitive renewal demonstrates MSKCC's ongoing commitment to the successful training of academic medical oncologists. ..